drugset
drugset / Trial / NCT00334685

[S,S]-Reboxetine Add-On Trial

NCT00334685 ↗

Phase 2 Terminated 136 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with \[S,S\]-Reboxetine against pregabalin monotherapy in patients with PHN

Timeline

Start
2006-08-22
Primary completion
2007-10-04
Completion
2007-10-11

Outcome

Outcome not reported

Stopped: “The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg Oral
Subject Pregabalin Small molecule 150 mg Oral
Subject Pregabalin Small molecule 300 mg Oral
Subject Pregabalin Small molecule 600 mg Oral
Subject [S,S]-Reboxetine Unknown 2 mg Oral
Subject [S,S]-Reboxetine Unknown 4 mg Oral
Subject [S,S]-Reboxetine Unknown 6 mg Oral

Indications

No indication recorded.